| --- |
| title: "House Oversight: Estate Documents (Nov 12) (HOUSE_OVERSIGHT_024025)" |
| source: "House Oversight: Estate Documents (Nov 12)" |
| sourceUrl: "https://www.justice.gov/epstein" |
| date: "2026-01-01" |
| category: "House Oversight" |
| eftaNumber: "HOUSE_OVERSIGHT_024025" |
| ocrPages: 1 |
| ocrChars: 3689 |
| ocrElapsed: 0.0 |
| parseTier: "external-legacy" |
| engine: "engine undisclosed (ep-nov-12.greg.technology mirror)" |
| externalSource: "greg-ep-nov-12" |
| externalLicense: "not granted" |
| externalCredit: "ep-nov-12.greg.technology" |
| externalUrl: "https://ep-nov-12.greg.technology" |
| --- |
| |
| OTHER INVESTMENT PROFESSIONALS |
| Kathy LaPorte, (52), Venture Partner, is an angel investor in the Digital Health space focusing |
| on evaluating and mentoring start-ups developing digital technology solutions for healthcare |
| consumers, providers, payers and the pharmaceutical/ medical device industries. Kathy is |
| affiliated with Health Tech Capital and is a Venture Partner with New Leaf, collaborating on |
| sourcing of opportunities with an emphasis on the Information Convergence sector. Kathy was |
| one of the founders of New Leaf upon its spin out from the Sprout Group in 2005. Kathy joined |
| the Sprout Group in 1993 and became a General Partner in 1994. Between 1987 and 1993, she |
| was a Principal at Asset Management Company, a venture capital firm focused on early stage |
| investments. Kathy received an M.B.A. from Stanford University Graduate School of Business |
| (Arjay Miller Scholar), and a B.S., summa cum laude, Phi Beta Kappa from Yale University. |
| Mark Charest, Ph.D., (36), Portfolio Manager, joined New Leaf in 2012. Previously, Mark was |
| an Associate and Kauffman Fellow at Panorama Capital (2010-2012) focused on life sciences |
| investments. Mark previously worked as a Consultant at ZS Associates (2009) and as an |
| Associate at Great Point Partners (2007-2009), a healthcare-focused public and private equity |
| investment firm. |
| Prior to that, Mark held an operating role as a Medicinal Chemistry Lab |
| Manager at Novartis Institutes for BioMedical Research (2004-2007). Mark received his Ph.D. in |
| Chemistry and Chemical Biology from Harvard University as a National Science Foundation |
| Graduate Research Fellow. |
| Mike Dybbs, Ph.D., (39), Principal, joined New Leaf in 2009 and was promoted to Principal in |
| 2012. Mike is currently on the boards of directors of Advanced Cellular Diagnostics and |
| Versartis. Prior to joining New Leaf, Mike was a Principal at the Boston Consulting Group |
| (BCG) where he was a core member of their Health Care practice. Mike graduated magna cum |
| laude from Harvard University with an AB in biochemical sciences and received his Ph.D. in |
| molecular biology and genetics from UC Berkeley, where he was awarded a Howard Hughes |
| Medical Institute fellowship. His research had been published in peer-reviewed journals, |
| including Neuron, Science and Nature. |
| Eric Kim, (28), Associate, joined New Leaf in December 2013. From 2011 through 2013, Eric was |
| a Private Equity Associate at Francisco Partners, where he focused on diligence and company |
| oversight efforts on the firm's healthcare information technology portfolio. Prior to joining |
| Francisco Partners, Eric worked for three years at McKinsey & Company as a Senior Business |
| Analyst in their Corporate Finance Practice. Eric received his dual B.A. in Mathematical |
| Methods in the Social Sciences and Economics from Northwestern University. |
| Isaac Manke, Ph.D., (37), Portfolio Manager, joined New Leaf in 2009 as an Associate and was |
| promoted to Public Investment Director in 2012. Prior to joining New Leaf, Isaac was an |
| Associate in the Global Biotechnology Equity Research group at Sanford C. Bernstein. |
| Previously, Isaac worked as an Associate in the Biotechnology Equity Research group at |
| Deutsche Bank and was a Senior Analyst at Health Advances, a biopharmaceutical and medical |
| device strategy consulting firm. Isaac received a B.A. in Biology and a B.A. in Chemistry at |
| Minnesota State University (Moorhead), and a Ph.D. in Biophysical Chemistry and Molecular |
| Structure at the Massachusetts Institute of Technology (MIT). Isaac's discoveries led to several |
| publications in top journals, including Science and Cell, and were selected by Science as one of |
| 14 |
| CONTROL NUMBER 257 - CONFIDENTIAL |
| HOUSE_OVERSIGHT_024025 |
|
|
